Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company VIVUS has received a distressing two-star ranking.
With that in mind, let's take a closer look at VIVUS and see what CAPS investors are saying about the stock right now.
On CAPS, 16% of the 428 members who have rated VIVUS believe the stock will underperform the S&P 500 going forward.
This is not the company to own. The insiders have been selling. The drug itself has risks, which will turn off many potential subjects even if deemed safe for them to own. There are drug alternatives coming to market (ie [Arena Pharmaceuticals]) which will hurt [VIVUS]. Beware. [VIVUS] also cut prices, because the free trial did not boost sales.
If you want market-topping returns, you need to protect yourself from any undue risk. Luckily, we've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2013." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
The article Why VIVUS Is Poised to Keep Plunging originally appeared on Fool.com.